Kingston, RI, United States of America

Don Engleman


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Don Engleman: Innovator in Pharmaceutical Compositions

Introduction

Don Engleman is a notable inventor based in Kingston, Rhode Island, who has made significant contributions to the field of pharmaceuticals. His work primarily focuses on developing compounds and compositions aimed at treating diseases characterized by acidic or hypoxic diseased tissues. Engleman's innovative approach has the potential to impact the treatment of various medical conditions.

Latest Patents

Engleman holds a patent for "Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues." This patent encompasses compounds designed for the treatment of diseases that exhibit acidic or hypoxic characteristics, along with pharmaceutical compositions that include these compounds. The patent also details methods for making and utilizing these innovative compounds and compositions.

Career Highlights

Engleman is currently associated with Cybrexa, Inc., a company dedicated to advancing cancer therapies. His role at Cybrexa allows him to leverage his expertise in pharmaceutical development, contributing to the creation of effective treatment options for patients.

Collaborations

Engleman collaborates with talented professionals in his field, including Daniel Richard Marshall and Johanna Marie Csengery. These partnerships enhance the innovative efforts at Cybrexa and foster a collaborative environment for research and development.

Conclusion

Don Engleman is a distinguished inventor whose work in pharmaceutical compositions is paving the way for new treatment options for diseases with challenging characteristics. His contributions to the field are invaluable and reflect a commitment to improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…